KRAS and lung cancer: Pharmacologic inhibition of SHP2, including SHP099 and RMC-4550, could suppress the growth of various tumors harboring KRAS mutations, such as pancreatic and lung cancers, via regulating RAS/MAPK signaling (Nichols et al., 2018; Hao et al., 2019).